PLA2G1B and pancreatic ductal adenocarcinoma: We thus tested the plasma of patients with pancreatic ductal adenocarcinoma (PDAC) for the presence of inhibitory PLA2G1B activity that impairs the CD4 T-cell response to IL-7.